An unusual case of risperidone instability in a fatality presenting an analytical and interpretative challenge

Drug Testing and Analysis

Volumn 5, Issue 9-10, 2013, Pages 748-752

  Taylor, Kerry ^a   Elliott, Simon ^a  

^a Inverness Medical Innovations   (United States)

Author keywords

Benzisoxazole scission; Paroxetine; Risperidone

Indexed keywords

BACTERIA; BIOMOLECULES; BLOOD; DRUG PRODUCTS; MAMMALS;

ANALYTICAL CHALLENGE; ANTIPSYCHOTIC DRUG; BENZISOXAZOLE SCISSION; BREAKDOWN PRODUCTS; GUT BACTERIA; HYDROXY METABOLITES; INTERPRETATIVE CHALLENGES; PAROXETINE; POST MORTEM; RISPERIDONE;

METABOLITES;

RISPERIDONE;

ADULT; ARTICLE; AUTOPSY; BLOOD SAMPLING; CASE REPORT; DRUG BLOOD LEVEL; DRUG STABILITY; DRUG URINE LEVEL; FATALITY; HUMAN; IN VITRO STUDY; MALE; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; URINALYSIS;

BENZISOXAZOLE SCISSION; PAROXETINE; RISPERIDONE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; AUTOPSY; DRUG STABILITY; HUMANS; MALE; PAROXETINE; RISPERIDONE; SCHIZOPHRENIA, PARANOID;

EID: 84886099668     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1503     Document Type: Article

References (14)

1. D.S. Ravin, J.W. Levenson. Fatal cardiac event following initiation of risperidone therapy. Ann. Pharmacother. 1997, 31, 867.
2. F. Rajabi, F. Hajsheikholeslami, N. Beyraghi. Sudden cardiac death after treatment with low dose risperidone in combination with cotrimoxazole. Asian J. Psychiatry 2011, 4, 218.
3. A.C. Springfield, E. Bodiford. An overdose of risperidone. J. Anal. Toxicol. 1996, 20, 202.
4. K.E. Goeringer, O. Drummer. Postmortem concentrations of risperidone. Bull. Int. Assoc. Toxicol. 2002, 32, 9.
5. M. Vermeir, I. Naessens, B. Remmerie, G. Mannens, J. Hendrickx, P. Sterkens, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 2008, 36, 769.
6. H.D. Yoo, H.Y. Cho, S.N. Lee, H. Yoon, Y.B. Lee. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J. Pharmacokinet. Pharmacodyn. 2012, 39, 329.
7. G. Mannens, M.L. Huang, W. Meuldermans, J. Hendrickx, R. Woestenborghs, J. Heykants. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 1993, 21, 1134.
8. W. Meuldermans, J. Hendrickx, G. Mannens, K. Lavrijsen, C. Janssen, J. Bracke, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispos. 1994, 22, 129.
9. D.M. Butzbach, P.C. Stockham, H.J. Kobus, D.N. Sims, R.W. Byard, R.J. Lokan, et al. Bacterial degradation of risperidone and paliperidone in decomposing blood. J. Forensic Sci. 2013, 58, 90.
10. S. Elliott, C. Smith. Investigation of the first deaths in the UK involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J. Anal. Toxicol. 2008, 32, 172.
11. S.P. Elliott, S.D. Brandt, S. Freeman, R.P. Archer. AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): An analytical challenge and implications for forensic analysis. Drug Test. Anal. 2013, 5(3), 196-202.
12. S.D. Karki, G.R. Masood. Combination risperidone and SSRI-induced serotonin syndrome. Ann. Pharmacother. 2003, 37, 388.
13. B.A. Sproule, C.A. Naranjo, K.E. Brenmer, P.C. Hassan. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin. Pharmacokinet. 1997, 33, 454.
14. M. Saito, N. Yasui-Furukori, T. Nakagami, H. Furukori, S. Kaneko. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J. Clin. Psychopharm. 2005, 25, 527.